Hospice Patients with Dementia Face Higher Risk from Certain Prescriptions

View Transcript

A study of those prescribed benzodiazepines or antipsychotics after hospice enrollment highlights two hospice policy issues. Read the full article on our website.

Transcript

Host: 

Welcome to Health Lab, your destination for news and stories about the future of healthcare. 

Today, we’re talking about hospice. More specifically, we’re diving into a recent study that found a link between common hospice drugs and a higher death risk in people with dementia. 

The study looked at hospice patients who were prescribed benzodiazepines or antipsychotics after hospice enrollment, and the findings highlight two significant hospice policy issues.

Hospice care aims to bring comfort, peace, and dignity to patients at the end of life.

Yet for the growing number of Americans with dementia who enter hospice, their course in hospice care is often long and unpredictable — making it especially important to ensure that the treatments hospice patients receive align with each person’s needs and stage of illness.

A recent University of Michigan study published in JAMA Network Open finds that medications commonly prescribed to ease symptoms such as agitation, anxiety, and delirium — benzodiazepines and antipsychotics — may carry major unintended risks for people with dementia receiving hospice care. 

Among more than 139,000 nursing home residents with Alzheimer’s disease and related dementias enrolled in hospice between the years of 2014 and 2018, those who began taking a benzodiazepine or an antipsychotic after enrollment were 41% and 16% more likely to die within six months, respectively, than very similar hospice patients with dementia who did not receive these medications. 

Dr. Lauren B. Gerlach, lead author and geriatric psychiatrist at the University of Michigan says, “Dementia is now the most common qualifying condition among hospice enrollees, yet many of these patients are not imminently dying. Because prognosis in dementia is so difficult to determine, nearly 1 in 5 patients will outlive the six-month eligibility window for hospice. This makes it critical that medications used during this period enhance, rather than diminish, quality of life.”

The study analyzed national Medicare data from a rare period when hospices were required to report prescribing information.

None of the patients studied had received the benzodiazepines or antipsychotics in the six months before entering hospice.

Despite this, nearly half (48%) of the patients received a new benzodiazepine prescription and 13% received an antipsychotic after hospice enrollment, and most within the first few days of admission to hospice.

The average hospice stay of patients in the study was more than 130 days, indicating that most patients were not in the final days or weeks of life.

Benzodiazepines include medications such as Ativan and Valium, while antipsychotics include medications such as Haldol and Zyprexa.

Dr. Gerlach says, “These early prescribing patterns suggest that these medications may sometimes be used as part of standard hospice care practices rather than fully tailored to each individual.” She goes on, “For many patients, these medications can provide meaningful relief from distressing symptoms, but they also carry risks. Our findings highlight an opportunity for hospice teams to regularly reassess medication use, especially early in care, when maintaining communication and alertness may be prioritized by patients and families.”

Both drug classes have well-established risks in older adults, including confusion, sedation and falls.

The U.S. Food and Drug Administration requires boxed warnings on the packaging of antipsychotics for increased mortality in patients with dementia.

Similar concerns have also been raised about benzodiazepines.

The study showed a mismatch between hospice policy and dementia care guidelines, with the findings pointing to two major policy gaps.

First, there is little ongoing oversight of medication use in hospice.

Hospice agencies were only required to report detailed prescribing data to the federal government for just four years, between 2014 and 2018, making that brief window of time the only period when researchers could study national prescribing patterns. 

“Right now, hospice prescribing is a black box,” Dr. Gerlach says.

“Medications covered under the hospice benefit are not reported to Medicare, so we have almost no visibility into what patients are receiving. That makes it impossible to monitor prescribing safety or quality on a national level.” 

And there is also a discrepancy in how medication use is monitored across care settings.

Both benzodiazepines and antipsychotics are tracked as part of nursing home quality reporting, and antipsychotic use directly impacts facility star ratings in the Centers for Medicare and Medicaid Services Care Compare Tool.

Yet these same medications are not tracked by hospice, leaving a gap in evaluating prescribing quality and reporting. 

Second, the six-month limit on Medicare hospice eligibility often does not align with the prolonged and uncertain course of dementia.

About 20% of hospice patients with dementia live longer than six months and are discharged from hospice, losing access to supportive services they still need.

“The Medicare hospice benefit was designed when most patients enrolling had cancer and short, predictable trajectories,” Dr. Gerlach says.

“For people with dementia, whose disease course can span years, we need care models and prescribing guidance that better reflect their experience.” 

The study findings show the need for dementia-specific hospice guidance. Dr. Gerlach’s team has previously shown wide variation across hospice agencies in their prescribing patterns of both classes of drugs, even after accounting for patient differences.

In national data, benzodiazepine prescribing ranged from 12% to 80% of hospice patients, and antipsychotic use from 6% to 62%.

Large and for-profit agencies were significantly more likely to prescribe these medications.

Last year, Dr. Gerlach’s group reported in JAMA Psychiatry that patients with dementia enrolled in hospice were three times more likely to receive benzodiazepines and antipsychotics than similar patients who were not in hospice. 

“Such wide variation suggests, in some cases, prescribing may be driven by hospice agency culture or policies, and given our findings linking new use of these medications with higher mortality, this inconsistency may have real consequences for patient outcomes,” Dr. Gerlach says.

With 60% of people with dementia now entering hospice at least once, and the proportion of hospice patients with dementia continuing to rise, Dr. Gerlach says these findings highlight the need for greater dementia-specific hospice quality measures and prescribing guidance.

“We need better transparency in prescribing data and support for hospice clinicians to make more evidence-informed, individualized decisions about how to best care for patients with dementia at end of life.”

A reminder that all Health Lab content including health news, best practices and research insights are for informational purposes only, and are not a substitute for professional medical guidance. Always seek the advice of a health care provider for questions about your health and treatment options.

For more on this story and for others like it, visit michiganmedicine.org/health-lab where you can also subscribe to our Health Lab newsletters to receive the latest in health, wellness and medical research information to your inbox each week. Health Lab is a part of the Michigan Medicine Podcast Network, and is produced by the Michigan Medicine Department of Communication. You can subscribe to Health Lab wherever you listen to podcasts.